Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Current Assets (2016 - 2025)

United Therapeutics' Current Assets history spans 17 years, with the latest figure at $3.7 billion for Q4 2025.

  • For Q4 2025, Current Assets fell 4.42% year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $3.7 billion, down 4.42%, while the annual FY2025 figure was $3.7 billion, 4.42% down from the prior year.
  • Current Assets for Q4 2025 was $3.7 billion at United Therapeutics, up from $3.5 billion in the prior quarter.
  • Across five years, Current Assets topped out at $4.0 billion in Q3 2024 and bottomed at $2.0 billion in Q1 2021.
  • The 5-year median for Current Assets is $3.3 billion (2022), against an average of $3.2 billion.
  • The largest annual shift saw Current Assets surged 45.48% in 2022 before it decreased 12.66% in 2025.
  • A 5-year view of Current Assets shows it stood at $2.3 billion in 2021, then soared by 45.48% to $3.4 billion in 2022, then grew by 5.05% to $3.6 billion in 2023, then increased by 9.09% to $3.9 billion in 2024, then fell by 4.42% to $3.7 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Current Assets are $3.7 billion (Q4 2025), $3.5 billion (Q3 2025), and $3.8 billion (Q2 2025).